Andere talen Syngene International Limited

Aandelen

SYNGENE

INE398R01022

Beurs gesloten - NSE India S.E. Andere beurzen 13:43:49 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
680,5 ^INR	-0,98%		-2,66%	-2,99%

26/04	SYNGENE INTERNATIONAL LIMITED : Jefferies & Co. verlaagt advies van Neutraal naar Verkopen	ZM
25/04	Transcript : Syngene International Limited, Q4 2024 Earnings Call, Apr 25, 2024

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Syngene International Limited Submits an Appeal to the National Faceless Appeal Centre, for Assessment Year 2022-23	28/04
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2017-18 and 2018-19	24/04
Syngene International Limited Recommends Final Dividend for the Financial Year 2024	24/04
Syngene International Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	24/04
Syngene International Limited Reports Earnings Results for the Full Year Ended March 31, 2024	24/04
Syngene International Limited Submits an Appeal to the Commissioner of Income-Tax-12, Bangalore, for Assessment Year 2013-14 and 2014-15	22/04
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes	12/04
Syngene Biologics Manufacturing Facility to Be Operational for U.S. and European Customers from Mid-Year	14/03
Bristol Myers CEO says India to have largest R&D presence outside US by 2025	27/02
Syngene International Posts Gains in Fiscal Q3 Consolidated Net Profit	26/01
Syngene International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	25/01
Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024	25/01
Syngene International Completes Acquisition of Stelis Biopharma's Biologics Plant	04/12
Syngene International Limited completed the acquisition of Unit 3 biologics manufacturing facility in Bangalore from Stelis Biopharma Private Limited for INR 6.2 billion.	01/12
FOCUS -Indian drug manufacturers benefit from Big Pharma interest beyond China	27/11
Syngene International COO Steps Down	31-10-23
Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024	31-10-23
Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director	25-10-23
Syngene International's Consolidated Profit Jumps in Fiscal Q2; Shares Slump 7%	18-10-23
Syngene International Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	17-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Syngene International Limited

Aandelen

SYNGENE

INE398R01022

Andere talen

Filters